1. Home
  2. TLSA vs UONEK Comparison

TLSA vs UONEK Comparison

Compare TLSA & UONEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$0.95

Market Cap

145.1M

Sector

Health Care

ML Signal

HOLD

Logo Urban One Inc. Class D

UONEK

Urban One Inc. Class D

N/A

Current Price

$3.61

Market Cap

19.9M

ML Signal

N/A

Company Overview

Basic Information
Metric
TLSA
UONEK
Founded
2013
1980
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Broadcasting
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
145.1M
19.9M
IPO Year
2017
1999

Fundamental Metrics

Financial Performance
Metric
TLSA
UONEK
Price
$0.95
$3.61
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 553.2K
3.4K
Earning Date
05-04-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $439,098,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.76
$0.45
52 Week High
$2.33
$9.38

Technical Indicators

Market Signals
Indicator
TLSA
UONEK
Relative Strength Index (RSI) 49.82 35.13
Support Level $0.90 $3.58
Resistance Level $1.20 $5.05
Average True Range (ATR) 0.09 0.22
MACD 0.01 -0.03
Stochastic Oscillator 62.70 15.00

Price Performance

Historical Comparison
TLSA
UONEK

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

About UONEK Urban One Inc. Class D

Urban One Inc is an urban oriented, multi-media company. Its business is radio broadcasting franchise that is the radio broadcasting operation that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment includes all the broadcasting related operations. The Reach Media segment consists of the Tom Joyner Morning Show and its related activities. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One's operations.

Share on Social Networks: